Renata Q1 profit rises on export growth and lower finance costs

Highlights

Renata's consolidated net profit rises 37% year on year to Tk 102 crore in Q1 FY26-27, driven by higher exports and lower finance costs.
International exports surge 59% to Tk 109 crore, while consolidated revenue increases 11% to Tk 1,260 crore, with contract manufacturing revenue up 102%.
Gross debt drops by Tk 521 crore to Tk 1,483 crore, reducing net financing costs 35.2% and improving net operating cash flow per share 74% to Tk 21.98.

Quarterly earnings and debt reduction

As reported by The Business Standard, citing Renata PLC in a company press release, consolidated net profit rises 37% year on year to Tk 102 crore in the first quarter of fiscal 2026-27, while standalone profit increases 45% to Tk 98 crore in July-September 2026.

Consolidated revenue climbs 11% to Tk 1,260 crore from Tk 1,131 crore a year earlier, and standalone revenue grows 12% to Tk 1,250 crore. Domestic pharmaceutical sales increase 8.6% to Tk 991 crore, animal health revenue rises 10% to Tk 197 crore, and contract manufacturing revenue more than doubles, up 102% to Tk 65 crore.

International exports, including contributions from overseas subsidiaries, surge 59% to Tk 109 crore, pointing to a wider overseas footprint. The company says higher gross profit and lower financing costs are the main drivers of earnings growth, with gross profit up 12.7%, ahead of the 10.5% rise in cost of sales.

Renata also cuts gross debt by Tk 521 crore during the quarter, reducing it to Tk 1,483 crore from Tk 2,004 crore. After adjusting for cash and fixed deposit receipts worth Tk 398 crore, net debt stands at Tk 1,085 crore, helping reduce net financing costs by 35.2% alongside lower foreign exchange losses and better working capital management.

Operational pressures and overseas expansion

Factory overhead costs rise 5.4%, which the company attributes to disciplined procurement and cost management. Even so, changes in product mix, especially higher sales of lower-margin tender-driven contract manufacturing products, put some pressure on margins.

On key market indicators, consolidated earnings per share rise 37% to Tk 8.87 in Q1 FY27. Net operating cash flow per share increases 74% to Tk 21.98, while net asset value per share edges up 3% to Tk 339.31.

Looking ahead, Renata says geopolitical conflicts, volatility in energy supplies and higher domestic utility costs continue to challenge operations. To limit export risks tied to reductions in U.S.-funded programmes and global inflationary pressures, the company is investing in research and development as it expands its injectables and anticancer therapeutics business across 77 international markets.

Our earlier coverage on geopolitical tensions and high borrowing costs explained how persistent shocks and elevated fiscal spending can raise refinancing risks and strain credit conditions, especially in emerging and frontier markets. We noted that conflicts have been pushing up energy and food prices, keeping inflation pressures elevated and, in turn, sustaining a more challenging funding environment.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.